Marie-Anne Goyette, Laura E Stevens, Carolyn R DePinho, Marco Seehawer, Jun Nishida, Zheqi Li, Callahan M Wilde, Rong Li, Xintao Qiu, Alanna L Pyke, Stephanie Zhao, Klothilda Lim, Gabrielle S Tender, Jason J Northey, Nicholas M Riley, Henry W Long, Carolyn R Bertozzi, Valerie M Weaver, Kornelia Polyak
Brain metastatic breast cancer is particularly lethal largely due to therapeutic resistance. Almost half of the patients with metastatic HER2-positive breast cancer develop brain metastases, representing a major clinical challenge. We previously described that cancer-associated fibroblasts are an important source of resistance in primary tumors. Here, we report that breast cancer brain metastasis stromal cell interactions in 3D cocultures induce therapeutic resistance to HER2-targeting agents, particularly to the small molecule inhibitor of HER2/EGFR neratinib...
May 14, 2024: Proceedings of the National Academy of Sciences of the United States of America